Claudia Mehedințu

No ORCID on file · 29 papers in corpus · active 2014-2025

Study types

  • article 23
  • review 4
  • case-report 2

Condition tags

  • endometriosis 29
  • dysmenorrhea 8
  • infertility 5
  • mesh:D004715 5
  • dyspareunia 4
  • chronic_pelvic_pain 2
  • die_deep_infiltrating 2
  • bladder_endometriosis 1
review 2025
Journal of clinical medicine ·doi:10.3390/jcm14072158

Endometriosis is a non-malignant, inflammatory condition that impacts individuals across various hormonal stages, including before their first menstruation, throughout their reproductive years, and after menopause. This condition arises whe…

case-report 2025
Life (Basel, Switzerland) ·doi:10.3390/life15101533

Erythema ab igne (EAI), also known as "hot water bottle rash" or "toasted skin syndrome", is a benign cutaneous condition caused by chronic exposure to low-level infrared heat. It typically begins as transient erythema and evolves into a re…

case-report 2025
Diagnostics ·doi:10.3390/diagnostics15192460

Background: Polypoid endometriosis is a rare variant of endometriosis that presents as a tumorous mass, making it difficult to differentiate it from a malignant tumor. It usually occurs in perimenopausal women or those undergoing hormone th…

article 2024
·doi:10.26416/obsgin.72.1.2024.9560

Endometriosis is a hormone-dependent disorder that affects the female reproductive system. It is defined by the growth of endometrial-like tissue outside the uterus. The disease can be found in various anatomical areas such as the peritoneu…

article 2023
·doi:10.1097/01.aog.0000929844.43483.20

INTRODUCTION: Relugolix combination therapy (Relugolix-CT: relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) significantly improved endometriosis-associated pain versus placebo in the SPIRIT 1&2 studies. Efficacy was maintained…

article 2023
·doi:10.1016/j.jmig.2023.08.031
article 2023
·doi:10.1093/humrep/dead093.032

Abstract Study question To assess the effect of oral relugolix combination therapy (Relugolix-CT) in the subgroup of women with endometriosis-associated pain who received prior first-line hormonal treatment. Summary answer Relugolix-CT sign…

article 2022
·doi:10.1016/j.ejogrb.2021.11.131
article 2022
·doi:10.1016/j.fertnstert.2022.08.020
review 2022
Diagnostics ·doi:10.3390/diagnostics12071767

(1) Background: Endometriosis is a widespread gynecological condition that causes chronic pelvic discomfort, dysmenorrhea, infertility, and impaired quality of life in women of reproductive age. Clinical examination, transvaginal ultrasonog…

article 2021
·doi:10.26416/gine.31.1.2021.4328

Deep infiltrating endometriosis (DIE) is defined as the in­fil­tra­tion of endometriotic implants deeper than 5 mm from the peritoneal surface. When the lesions infiltrate the mus­cu­laris propria layer of the rectum or sigmoid, we talk abo…

article 2021
·doi:10.31689/rmm.2021.28.2.215

Colorectal deep infiltrative endometriosis (DIE) can have a major impact on patient’s health and quality of life. Surgical treatment of colorectal DIE varies depending on the location and characteristics of the lesions, which is why the pre…

article 2021
·doi:10.26416/obsgin.69.1.2021.4792

We conducted this observational prospective study in order to establish to what extent do the clinical and paraclinical characteristics of the patient and the factors that determine infertility also negatively influence pregnancy rate (PR) …

article 2021

We conducted this observational prospective study in order to establish to what extent do the clinical and paraclinical characteristics of the patient and the factors that determine infertility also negatively influence pregnancy rate (PR) …

review 2021
Medicina (Kaunas, Lithuania) ·doi:10.3390/medicina57111258

The connection between endometriosis and pregnancy outcomes is trending among the research topics. Until recently, endometriosis and its painful symptomatology were considered to be alleviated by pregnancy. However, these beliefs have shift…

article 2021
·doi:10.1093/humrep/deab126.056

Abstract Study question To assess the efficacy of Relugolix-CT vs placebo in women who were surgically diagnosed with endometriosis <5 and > = 5 years ago. Summary answer Treatment outcomes did not differ for dysmenorrhea and daily fu…

article 2021
·doi:10.1093/humrep/deab126.057

Abstract Study question To assess the long-term (52-week) efficacy and safety of relugolix combination therapy (Relugolix-CT) in the treatment of endometriosis-associated pain. Summary answer Relugolix-CT demonstrated a sustained improvemen…

article 2021
Journal of clinical medicine ·doi:10.3390/jcm10215211

Morbidity and mortality alone are not comprehensive measures of evaluating the benefits of surgical interventions in endometriosis patients, thus, subjective patient-reported instruments are required. The 36-tem Short Form Survey (SF-36) is…

article 2021
·doi:10.1016/j.fertnstert.2021.07.146
article 2021
·doi:10.1016/j.jmig.2021.09.031
article 2021
·doi:10.1016/j.jmig.2021.09.032
article 2019
·doi:10.37358/rc.19.8.7444

Endometriosis is a benign gynecological pathology that mostly affects the organs of the pelvis,but also organs located at a distance maybe affected. Tissue immunohistochemically identified as ectopic endometrium may undergo certain structur…

review 2018
·doi:10.22543/7674.52.p158162

Abdominal-pelvic pain is the dominant symptom in endometriosis, one of the most common pathologies that affect women, being also a multifactorial disorder. Exploratory laparoscopy allows the correct assessment of the location as well as sev…

article 2018
Journal of minimally invasive gynecology ·doi:10.1016/j.jmig.2018.01.019
article 2018
·doi:10.37358/rc.18.3.6153

Endometriosis, one of the most common gynecologic pathologies, is defined as an inflammatory, estrogen-dependent disease characterized by the growth of endometrial stroma and glands outside the uterine cavity. It is a multifactorial disease…